New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
05:12 EDTREGNRegeneron's Eylea Injection approved by European Commission
Regeneron Pharmaceuticals announced that Eylea Injection has been approved by the European Commission for the treatment of patients with neovascular, or wet, age-related macular degeneration, also known as wet AMD. According to the European Medicines Agency, or EMA, approved Summary of Product Characteristics, Eylea treatment is initiated with one 2 mg injection per month for three consecutive months, followed by one injection every two months. There is no requirement for monitoring by the physician between injections. After the first twelve months of treatment with Eylea, the treatment interval may be extended based on visual and anatomic outcomes. In such cases, the frequency of monitoring visits is determined by the treating physician and may be more often than the schedule of injections.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
07:54 EDTREGNLeerink to hold a bus tour
Subscribe for More Information
06:15 EDTREGNUnitedHealth unit prefers Sanofi, Regeneron cholesterol shot, Bloomberg says
Subscribe for More Information
November 24, 2015
05:23 EDTREGNSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use